Real-world treatment patterns and clinical outcomes in patients with locally advanced or metastatic urothelial carcinoma in Germany: retrospective CONVINCE study
Abstract Purpose CONVINCE is a retrospective medical chart review study that examined demographics, treatment patterns, and outcomes in patients who received first-line (1L) treatment for locally advanced or metastatic urothelial carcinoma (la/mUC) in Germany. Methods Eligible patients were adults w...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-03-01
|
| Series: | Journal of Cancer Research and Clinical Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s00432-025-06131-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849699102172905472 |
|---|---|
| author | Katrin Schlack Stefan Machtens Thomas Kubin Markus Ruhnke Clemens Schulte Anna Eisen Ulrike Osowski Silke Guenther Mairead Kearney Rainer Lipp Stephan Schmitz |
| author_facet | Katrin Schlack Stefan Machtens Thomas Kubin Markus Ruhnke Clemens Schulte Anna Eisen Ulrike Osowski Silke Guenther Mairead Kearney Rainer Lipp Stephan Schmitz |
| author_sort | Katrin Schlack |
| collection | DOAJ |
| description | Abstract Purpose CONVINCE is a retrospective medical chart review study that examined demographics, treatment patterns, and outcomes in patients who received first-line (1L) treatment for locally advanced or metastatic urothelial carcinoma (la/mUC) in Germany. Methods Eligible patients were adults with confirmed la/mUC who received any systemic 1L anticancer treatment between January 1, 2019, and September 30, 2021, outside of a clinical trial. Patients were grouped by type of 1L treatment: platinum-based chemotherapy (PBC), immune checkpoint inhibitor (ICI), or other treatments. Follow-up was ≥ 6 months after end of PBC or start of ICI or other treatments. The primary objective was measurement of real-world progression-free survival (rwPFS). Results Data were collected from 188 patients treated at 27 sites (hospitals or office-based practices). First-line treatment was PBC in 76.1% of patients, ICI in 19.1%, and other treatments in 4.8%. The most common PBC regimen was cisplatin + gemcitabine (72.7%), and the most common ICI was atezolizumab (44.4%); 4.2% of PBC-treated patients received avelumab 1L maintenance. In patients who received 1L PBC, ICI treatment, or other treatments, median (95% CI) rwPFS was 10.5 months (9.2–11.6), 12.6 months (8.9–22.9), and not evaluable; median (95% CI) real-world overall survival was 18.1 months (16.5–19.0), 15.9 months (11.1–24.5), and not evaluable; and objective response rates were 56.6%, 60.0%, and 83.3%, including complete response in 14.0%, 20.0%, and 0%, respectively. Conclusion PBC was the most common 1L treatment in patients with la/mUC in Germany, consistent with treatment guidelines. Future studies are needed to assess outcomes with newer treatments. |
| format | Article |
| id | doaj-art-242bb71e4e0a4d3c8c2c2d627e93dcdc |
| institution | DOAJ |
| issn | 1432-1335 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Springer |
| record_format | Article |
| series | Journal of Cancer Research and Clinical Oncology |
| spelling | doaj-art-242bb71e4e0a4d3c8c2c2d627e93dcdc2025-08-20T03:18:42ZengSpringerJournal of Cancer Research and Clinical Oncology1432-13352025-03-01151311110.1007/s00432-025-06131-yReal-world treatment patterns and clinical outcomes in patients with locally advanced or metastatic urothelial carcinoma in Germany: retrospective CONVINCE studyKatrin Schlack0Stefan Machtens1Thomas Kubin2Markus Ruhnke3Clemens Schulte4Anna Eisen5Ulrike Osowski6Silke Guenther7Mairead Kearney8Rainer Lipp9Stephan Schmitz10Department of Urology, University Hospital MuensterDepartment of Urology, GFO Hospitals Rhein-Berg, Marien-HospitalDepartment Für Hematology, Oncology and Palliative Care, Kliniken Südostbayern AG, Klinikum TraunsteinClinic for Hematology, Oncology and Palliative Medicine, Helios Klinikum AuePractice for Hematology and OncologyGermanOncology GmbHMerck Healthcare Germany GmbH, Weiterstadt, Germany, an affiliate of Merck KGaAMerck Healthcare KGaA, BioNTech SEMerck Healthcare KGaA, BioNTech SEGermanOncology GmbHMedical Care Center for Oncology and HematologyAbstract Purpose CONVINCE is a retrospective medical chart review study that examined demographics, treatment patterns, and outcomes in patients who received first-line (1L) treatment for locally advanced or metastatic urothelial carcinoma (la/mUC) in Germany. Methods Eligible patients were adults with confirmed la/mUC who received any systemic 1L anticancer treatment between January 1, 2019, and September 30, 2021, outside of a clinical trial. Patients were grouped by type of 1L treatment: platinum-based chemotherapy (PBC), immune checkpoint inhibitor (ICI), or other treatments. Follow-up was ≥ 6 months after end of PBC or start of ICI or other treatments. The primary objective was measurement of real-world progression-free survival (rwPFS). Results Data were collected from 188 patients treated at 27 sites (hospitals or office-based practices). First-line treatment was PBC in 76.1% of patients, ICI in 19.1%, and other treatments in 4.8%. The most common PBC regimen was cisplatin + gemcitabine (72.7%), and the most common ICI was atezolizumab (44.4%); 4.2% of PBC-treated patients received avelumab 1L maintenance. In patients who received 1L PBC, ICI treatment, or other treatments, median (95% CI) rwPFS was 10.5 months (9.2–11.6), 12.6 months (8.9–22.9), and not evaluable; median (95% CI) real-world overall survival was 18.1 months (16.5–19.0), 15.9 months (11.1–24.5), and not evaluable; and objective response rates were 56.6%, 60.0%, and 83.3%, including complete response in 14.0%, 20.0%, and 0%, respectively. Conclusion PBC was the most common 1L treatment in patients with la/mUC in Germany, consistent with treatment guidelines. Future studies are needed to assess outcomes with newer treatments.https://doi.org/10.1007/s00432-025-06131-yTreatment patternsTreatment outcomeImmune checkpoint inhibitorsUrothelial carcinoma |
| spellingShingle | Katrin Schlack Stefan Machtens Thomas Kubin Markus Ruhnke Clemens Schulte Anna Eisen Ulrike Osowski Silke Guenther Mairead Kearney Rainer Lipp Stephan Schmitz Real-world treatment patterns and clinical outcomes in patients with locally advanced or metastatic urothelial carcinoma in Germany: retrospective CONVINCE study Journal of Cancer Research and Clinical Oncology Treatment patterns Treatment outcome Immune checkpoint inhibitors Urothelial carcinoma |
| title | Real-world treatment patterns and clinical outcomes in patients with locally advanced or metastatic urothelial carcinoma in Germany: retrospective CONVINCE study |
| title_full | Real-world treatment patterns and clinical outcomes in patients with locally advanced or metastatic urothelial carcinoma in Germany: retrospective CONVINCE study |
| title_fullStr | Real-world treatment patterns and clinical outcomes in patients with locally advanced or metastatic urothelial carcinoma in Germany: retrospective CONVINCE study |
| title_full_unstemmed | Real-world treatment patterns and clinical outcomes in patients with locally advanced or metastatic urothelial carcinoma in Germany: retrospective CONVINCE study |
| title_short | Real-world treatment patterns and clinical outcomes in patients with locally advanced or metastatic urothelial carcinoma in Germany: retrospective CONVINCE study |
| title_sort | real world treatment patterns and clinical outcomes in patients with locally advanced or metastatic urothelial carcinoma in germany retrospective convince study |
| topic | Treatment patterns Treatment outcome Immune checkpoint inhibitors Urothelial carcinoma |
| url | https://doi.org/10.1007/s00432-025-06131-y |
| work_keys_str_mv | AT katrinschlack realworldtreatmentpatternsandclinicaloutcomesinpatientswithlocallyadvancedormetastaticurothelialcarcinomaingermanyretrospectiveconvincestudy AT stefanmachtens realworldtreatmentpatternsandclinicaloutcomesinpatientswithlocallyadvancedormetastaticurothelialcarcinomaingermanyretrospectiveconvincestudy AT thomaskubin realworldtreatmentpatternsandclinicaloutcomesinpatientswithlocallyadvancedormetastaticurothelialcarcinomaingermanyretrospectiveconvincestudy AT markusruhnke realworldtreatmentpatternsandclinicaloutcomesinpatientswithlocallyadvancedormetastaticurothelialcarcinomaingermanyretrospectiveconvincestudy AT clemensschulte realworldtreatmentpatternsandclinicaloutcomesinpatientswithlocallyadvancedormetastaticurothelialcarcinomaingermanyretrospectiveconvincestudy AT annaeisen realworldtreatmentpatternsandclinicaloutcomesinpatientswithlocallyadvancedormetastaticurothelialcarcinomaingermanyretrospectiveconvincestudy AT ulrikeosowski realworldtreatmentpatternsandclinicaloutcomesinpatientswithlocallyadvancedormetastaticurothelialcarcinomaingermanyretrospectiveconvincestudy AT silkeguenther realworldtreatmentpatternsandclinicaloutcomesinpatientswithlocallyadvancedormetastaticurothelialcarcinomaingermanyretrospectiveconvincestudy AT maireadkearney realworldtreatmentpatternsandclinicaloutcomesinpatientswithlocallyadvancedormetastaticurothelialcarcinomaingermanyretrospectiveconvincestudy AT rainerlipp realworldtreatmentpatternsandclinicaloutcomesinpatientswithlocallyadvancedormetastaticurothelialcarcinomaingermanyretrospectiveconvincestudy AT stephanschmitz realworldtreatmentpatternsandclinicaloutcomesinpatientswithlocallyadvancedormetastaticurothelialcarcinomaingermanyretrospectiveconvincestudy |